Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month High – Time to Buy?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)’s share price hit a new 52-week high during trading on Friday . The company traded as high as $43.73 and last traded at $42.7640, with a volume of 103178 shares. The stock had previously closed at $42.00.

Analyst Ratings Changes

Several research firms recently weighed in on KNSA. Wedbush restated an “outperform” rating and set a $48.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, December 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. The Goldman Sachs Group raised their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Citigroup lifted their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Finally, Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and an average price target of $52.00.

Kiniksa Pharmaceuticals International Stock Up 2.8%

The firm has a 50 day moving average of $40.21 and a 200-day moving average of $34.98. The company has a market cap of $3.27 billion, a P/E ratio of 95.98 and a beta of 0.02.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm had revenue of $180.86 million for the quarter, compared to the consensus estimate of $166.64 million. During the same period last year, the firm earned ($0.18) earnings per share. The company’s revenue for the quarter was up 61.2% on a year-over-year basis. On average, research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, CEO Sanj K. Patel sold 97,390 shares of the company’s stock in a transaction dated Wednesday, October 22nd. The shares were sold at an average price of $38.83, for a total value of $3,781,653.70. Following the completion of the sale, the chief executive officer directly owned 111,794 shares of the company’s stock, valued at $4,340,961.02. This represents a 46.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eben Tessari sold 12,048 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $41.56, for a total transaction of $500,714.88. Following the transaction, the chief operating officer directly owned 16,666 shares in the company, valued at $692,638.96. This trade represents a 41.96% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 553,057 shares of company stock valued at $21,582,372 over the last three months. 53.48% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP boosted its position in Kiniksa Pharmaceuticals International by 2.3% during the 3rd quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after acquiring an additional 90,194 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Kiniksa Pharmaceuticals International by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock worth $74,606,000 after acquiring an additional 151,604 shares in the last quarter. Acadian Asset Management LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 22.6% during the 2nd quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock worth $35,067,000 after purchasing an additional 233,668 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in Kiniksa Pharmaceuticals International by 45.3% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after purchasing an additional 332,846 shares in the last quarter. Finally, Qube Research & Technologies Ltd boosted its position in Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.